Clinical Trial Update: Bevacizumab Plus Somatostatin Analogue and Metronomic Capecitabine in Patients With Advanced Neuroendocrine Tumors [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating the combination of bevacizumab, a somatostatin analogue, and metronomic capecitabine in patients with advanced neuroendocrine tumors.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neuroendocrine Tumors

Drugs mentioned

• Bevacizumab (bevacizumab)
• Capecitabine (capecitabine)
• OCTREOTIDE (OCTREOTIDE ACETATE)

Snippet

Sponsor: University of Turin, Italy | Conditions: Neuroendocrine Carcinomas | Phase 2 | Status: UNKNOWN